Steven Cohen Protagonist Therapeutics, Inc Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 214,872 shares of PTGX stock, worth $8.44 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

214,872

Previous 909,734 76.38%

Holding current value

$8.44 Million

Previous $31.5 Million 69.37%

% of portfolio

0.03%

Previous 0.09%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $23.4 Million - $32.9 Million	-694,862 Reduced 76.38%	214,872 $9.66 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $7.16 Million - $10.1 Million	-290,168 Reduced 24.18%	909,734 $31.5 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $30.8 Million - $45.4 Million	-1,413,551 Reduced 54.09%	1,199,902 $34.7 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $21.1 Million - $35.3 Million	1,505,313 Added 135.84%	2,613,453 $59.9 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $18.5 Million - $26.2 Million	1,108,140 New	1,108,140 $18.5 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $3.41 Million - $8.03 Million	-316,500 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $16.4 Million - $24.8 Million	-2,221,493 Reduced 87.53%	316,500 $3.45 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $11.9 Million - $17.8 Million	-1,518,207 Reduced 37.43%	2,537,993 $21.4 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $8.06 Million - $29.1 Million	1,141,100 Added 39.14%	4,056,200 $32.1 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $11.6 Million - $17.9 Million	495,337 Added 20.47%	2,915,100 $69 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $34.7 Million - $73 Million	-1,967,537 Reduced 44.85%	2,419,763 $82.8 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $41.9 Million - $161 Million	3,232,100 Added 279.79%	4,387,300 $77.7 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $5.44 Million - $9.55 Million	212,900 Added 22.59%	1,155,200 $51.8 Million
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $7.46 Million - $12.2 Million	392,300 Added 71.33%	942,300 $24.4 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $10.2 Million - $13.8 Million	550,000 New	550,000 $11.1 Million
Q4 2019 Feb 14, 2020	SELL	$4.69 - $13.45 $762,125 - $2.19 Million	-162,500 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$9.41 - $16.56 $1.53 Million - $2.69 Million	162,500 New	162,500 $1.95 Million
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $1.02 Million - $2.77 Million	-120,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $1.74 Million - $2.5 Million	120,000	120,000 $2.5 Million

Others Institutions Holding PTGX

# of Institutions

248

Shares Held

56.7M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account